Livforsakringsbolaget Skandia’s Ionis Pharmaceuticals IONS Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,500	Closed	-$67K	–	673
2021 Q1	$67K	Hold	1,500	–	–	﹤0.01%	641
2020 Q4	$85K	Hold	1,500	–	–	0.01%	613
2020 Q3	$71K	Hold	1,500	–	–	0.01%	604
2020 Q2	$88K	Hold	1,500	–	–	0.01%	559
2020 Q1	$71K	Hold	1,500	–	–	0.01%	542
2019 Q4	$91K	Hold	1,500	–	–	0.01%	529
2019 Q3	$90K	Hold	1,500	–	–	0.01%	537
2019 Q2	$96K	Buy	+1,500	New	+$106K	0.01%	506
2016 Q4	–	Sell	-138,621	Closed	-$15.4M	–	698
2016 Q3	$15.4M	Buy	138,621 +126,921	+1,085%	+$3.97M	0.75%	19
2016 Q2	$273K	Hold	11,700	–	–	0.01%	663
2016 Q1	$474K	Hold	11,700	–	–	0.02%	619
2015 Q4	$725K	Hold	11,700	–	–	0.03%	509
2015 Q3	$473K	Hold	11,700	–	–	0.02%	596
2015 Q2	$673K	Hold	11,700	–	–	0.03%	557
2015 Q1	$745K	Buy	+11,700	New	+$794K	0.04%	549

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Livforsakringsbolaget Skandia's IONS Position: Q2 2021 in Review

Livforsakringsbolaget Skandia sold out of Ionis Pharmaceuticals (IONS) in Q2 2021, closing a stake of 1,500 shares — an estimated $67K sold.

Livforsakringsbolaget Skandia first reported a position in IONS in Q1 2015 and held it in 15 quarters. The position peaked at $15.4M in Q3 2016. 338 funds tracked by Wall St. Rank hold IONS as of Q2 2021.

Livforsakringsbolaget Skandia reported no remaining Ionis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 1,500 Ionis Pharmaceuticals shares in Q2 2021, an estimated $67K.
Livforsakringsbolaget Skandia first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 15 quarters.
Livforsakringsbolaget Skandia's Ionis Pharmaceuticals position peaked at $15.4M in Q3 2016.
338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2021.

Based on Livforsakringsbolaget Skandia's 13F filing for Q2 2021, filed 13 Jul 2021.